Such experimental approaches have successfully been employed to elucidate important aspects of the pathobiology of TP53-mutant AML/MDS (Boettcher et al, 2019; Sallman et al, 2020; Schimmer et al, 2022; Sellar et al, 2022; Thijssen et al, 2021). Here, TP53 is linked to acute myeloid leukemia.